methsuximide (Rx)

Brand and Other Names:Celontin
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

capsule

  • 150mg
  • 300mg
more...

Absence Seizures

300 mg PO qDay

Increase by 300 mg/week to no more than 1.2 g/day in divided doses

May take with food or milk

Monitor: CBC

Dosage Forms & Strengths

capsule

  • 150mg
  • 300mg
more...

Absence Seizures

<12 years: Not established

>12 years

  • 300 mg PO qDay
  • Increase by 300 mg/week to no more than 1.2 g/day in divided doses
  • May take with food or milk
  • Monitor: CBC

Absence seizures

300 mg PO qDay

Increase by 300 mg/week to no more than 1.2 g/day in divided doses

May take with food or milk

Monitor: CBC

Next:

Interactions

Interaction Checker

and methsuximide

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Common

            • Ataxia, dizziness, somnolence
            • Erythema
            • Abdominal pain, constipation, diarrhea, epigastric pain, loss of appetite, nausea, vomiting, weight loss
            • Hematuria, proteinuria

            Serious

            • Auditory hallucinations (rare), psychotic disorder (rare), suicidal behavior (rare)
            • Stevens-Johnson syndrome
            • Disorder of hematopoietic structure, leukopenia, monocytosis, pancytopenia
            • Systemic lupus erythematosus
            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Cautions

            Do not discontinue rapidly

            Succinimides have been associated with blood dyscrasias

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: avoid during breastfeeding

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Succinimide; depresses motor cortex, increases convulsive stimuli threshold in CNS

            Pharmacokinetics

            Half-Life: 3 hr

            Time: 1-3 hr

            Concentration: 3-7 mcg/mL (dose-dependent)

            Therapeutic plasma concentration: 10-40 mcg/mL

            Metabolism: Liver

            Excretion: Urine

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous